SCHEDULE: Jane Street Discloses Stake in Co-Diagnostics

Jane Street Group, LLC and its affiliates have filed a Schedule 13G, reporting beneficial ownership of 1.7% of Co-Diagnostics, Inc. common stock as of June 30, 2026.

Summary

• This filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership of Co-Diagnostics, Inc. common stock.
• Jane Street Group, LLC, along with affiliates Jane Street Capital, LLC and Jane Street Global Trading, LLC, are the reporting persons.
• The filing reports a total of 89,240 shares beneficially owned, representing 1.7% of the class of securities.
• This ownership is held with shared voting power and shared dispositive power.
• The reporting persons are registered as broker-dealers and are filing under Rule 13d-1(b).
• The date of the event requiring this filing is June 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to its nature as a Schedule 13G, indicating a passive investment stake rather than active strategic involvement or performance-related news.

Positives

• The filing indicates a significant financial institution, Jane Street, has taken a position in Co-Diagnostics, Inc., which could be interpreted as a sign of confidence in the company's long-term prospects by market participants.
• The aggregate beneficial ownership of 1.7% is a notable stake for a passive investor.

Negatives

• The filing is a Schedule 13G, which typically signifies passive investment and does not imply any active management or strategic involvement, thus offering limited insight into operational performance.
• The reporting persons hold the shares with shared voting and dispositive power, suggesting a coordinated but not necessarily controlling interest.

Risks

• As a Schedule 13G filing, it does not provide operational details or forward-looking statements, thus offering no direct insight into potential business risks or challenges faced by Co-Diagnostics, Inc.
• The passive nature of the investment means Jane Street's stake could be divested without prior notice, potentially impacting share price.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Co-Diagnostics, Inc. or the reporting persons.

Industry Context

StockSavvy.ai notes that Jane Street is a prominent quantitative trading firm and liquidity provider. Their acquisition of a stake in Co-Diagnostics, Inc., a company in the diagnostics sector, suggests a potential arbitrage or market-making opportunity, or a belief in the company's valuation, rather than an endorsement of its operational strategy.

Stakeholder Impact

• Shareholders may view the increased institutional interest from Jane Street as a positive signal, potentially leading to increased trading volume or price stability.
• The passive nature of the stake means no immediate impact on corporate governance or strategic direction is implied.

Next Steps

• Jane Street will continue to monitor its beneficial ownership of Co-Diagnostics, Inc. common stock.
• Further amendments to this Schedule 13G will be filed if changes in beneficial ownership occur.

Key Dates

Keywords

Co-Diagnostics, Jane Street, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Securities